Research Signal – Source date 2026-01-20
A five-day course of dasatinib plus quercetin improved several measures of kidney injury in diabetic male mice, even though it did not lower their blood sugar. The finding comes from a mouse study published on January 20, 2026, focused on whether a senolytic treatment could affect the diabetic kidney itself.
Senolytics are drugs intended to remove senescent cells. These cells have stopped dividing but remain metabolically active and can release inflammatory signals that affect surrounding tissue. The study does not show that the drug combination improves kidney function in people. It offers a kidney-focused preclinical result, alongside cultured human-cell experiments that help explain possible cellular responses.
The kidney result appeared after blood sugar stayed high
The researchers induced diabetes in male C57BL/6J mice with streptozotocin. At day 100, diabetic animals were assigned to five days of oral dasatinib plus quercetin or to vehicle, the treatment mixture without the active drug combination. The treatment group contained 13 mice, the diabetic vehicle group contained nine, and a separate non-diabetic control group contained 10 animals.
Fasting blood glucose was higher in diabetic mice than in non-diabetic controls, but did not differ between diabetic mice treated with dasatinib plus quercetin and those given vehicle. The kidney improvements were therefore not accompanied by lower fasting blood glucose.
The timing also matters. The mice received the short course after diabetes had already been established, and kidney tissues and measurements were assessed 20 days after treatment ended. This creates a useful post-treatment observation: the results were not simply measurements taken during drug exposure. It also leaves open how long any benefit might last. A single assessment 20 days later cannot establish indefinite durability or show what repeated courses would achieve.
The authors distinguish this experiment from earlier human observations described in the paper. In that earlier work, dasatinib plus quercetin was associated with changes in senescent-cell abundance and circulating inflammation, with observations involving adipose or epidermal tissue. Those findings provide background for the current study, but they are not human kidney outcomes.
Function and injury improved, but scarring was not uniformly reversed
Several measurements pointed toward less kidney injury in treated diabetic mice. Plasma creatinine was lower, which the study used as an indicator of improved kidney function. Glomerular injury scores were also lower, and urinary epidermal growth factor was higher. Kidney expression of LGALS3, also known as Mac-2, decreased. The diabetic vehicle group showed the expected kidney changes compared with non-diabetic controls, including greater glomerular injury and lower nephrin staining, a marker examined in the kidney’s filtration structures.
The pattern was not a universal normalization of kidney biology. Some measures, including HAVCR1 and TNFRSF1B, moved in a favorable direction without reaching statistical significance, and nephrin staining showed an increase that was described as a trend. The supplied findings do not establish a treatment-related reduction in urinary albumin, a specific percentage improvement, or normalization of every kidney measure.
Fibrosis results were similarly mixed. Diabetic mice had more trichrome staining and fibronectin staining than non-diabetic controls. Dasatinib plus quercetin reduced fibronectin staining and lowered several fibrosis-related transcripts, including TGFB1, FN1, and TNC, with a trend for lower INHBA. Trichrome staining, however, did not decrease significantly. A tissue stain that remained unchanged alongside other favorable markers is important context: the experiment supports reduced activity in some pathways associated with extracellular-matrix deposition, not complete reversal of kidney scarring.
Senescence and inflammatory markers changed alongside kidney measures
Cellular senescence is a state in which a cell stops dividing but remains active. Senescent cells can release a collection of cytokines, chemokines, growth factors and matrix-related proteins often called the senescence-associated secretory phenotype, or SASP. In diabetic kidney disease, persistent metabolic stress and inflammation may help create conditions in which these signals contribute to tissue dysfunction.
In the diabetic mice, kidney p16 and p21 were higher than in non-diabetic controls, and senescence-associated beta-galactosidase activity was also increased. After treatment, p16 was lower and p21 moved downward as a trend. The kidney also showed lower expression of inflammatory mediators including MCP-1 or CCL2, TNF, IL-1β and IL-6. These changes fit the study’s proposed senolytic explanation, in which reducing senescent-cell burden could lessen inflammatory signaling around the damaged tissue.
The inflammatory response was not uniform. The kidney macrophage abundance marker ADGRE1 did not fall significantly after treatment, even though MCP-1 and other inflammatory signals decreased. Lower inflammatory activity therefore should not be translated into a claim that the treatment removed a defined number of kidney macrophages.
The study also measured two geroprotective factors, SIRT1 and α-Klotho. Both increased in kidney tissue after dasatinib plus quercetin, while urinary α-Klotho did not differ among groups. The increase in kidney α-Klotho is a potentially relevant molecular change, but it does not demonstrate correction of a measured baseline α-Klotho deficiency in these diabetic mice. Nor does it demonstrate whole-body rejuvenation, increased lifespan or increased healthspan.
Coordinated changes in senescence markers, inflammatory signals and kidney outcomes make the proposed mechanism plausible, but they do not by themselves prove how much senescent-cell removal contributed to each outcome. The drug combination may affect several cell types and pathways, and the study’s measurements cannot assign every improvement to one mechanism.
Human cells helped separate cellular responses from whole-kidney effects
The researchers used cultured human cells to examine responses that are difficult to isolate inside an intact kidney. Human kidney tubular epithelial cells called HK2 were exposed to high glucose together with transforming growth factor beta 1. Human umbilical-vein endothelial cells, or HUVECs, were exposed to high glucose and tumor necrosis factor. U937-derived macrophages were exposed to high glucose and lipopolysaccharide.
These added stimuli were cell-specific ways of modeling inflammatory or profibrotic pressure alongside high glucose. In HK2 cells, the conditions increased NF-κB signaling, senescence markers and profibrotic features. Dasatinib plus quercetin reduced NF-κB activation, lowered p16 expression and eased several inflammatory or profibrotic changes while preserving cell viability in the reported experiment. The treatment also increased SIRT1 and Klotho expression in the relevant cell studies.
In the macrophage experiments, the high-glucose and lipopolysaccharide conditions promoted NF-κB activation, inflammatory gene expression and an M1-like marker. Dasatinib plus quercetin reduced NF-κB-related signals and lowered CCL2 and TNF expression. In HUVECs, the combination reduced senescence-associated markers and increased Klotho and SIRT1 expression under the tested conditions.
These cell experiments support a mechanistic interpretation, but they should not be merged with the whole-animal results. The cultured systems used selected concentrations and additional stimuli for defined periods. They showed reduced NF-κB activation in those settings, whereas NFKB1 expression in mouse kidney tissue was unchanged by diabetes or treatment. The difference illustrates why a cellular pathway result cannot simply be presented as a complete description of what happened across the kidney.
The study leaves a substantial translation gap
The experiment has a useful design for testing a short post-treatment effect, but its boundaries are specific. It used one chemically induced diabetes model, male mice only, and a bounded follow-up period. The authors note that female mice were not included because of historical resistance to this streptozotocin model and inconsistent kidney injury. That choice makes the findings interpretable within the selected model while limiting how broadly they can be generalized across sexes and forms of diabetes.
The study’s characterization of senescence also relied primarily on three of eight potential hallmarks discussed by the authors. Senescence can vary by disease, tissue and initiating stress, so the measured markers provide evidence of a senescence-related state without exhaustively identifying every senescent cell or proving that all beneficial effects came from eliminating them. The authors also identify the need to examine additional diabetic kidney disease models.
Most importantly, the human-cell experiments do not establish improved kidney function in treated patients, and the earlier human observations described by the paper concern adipose or epidermal senescence and circulating inflammatory factors rather than kidney outcomes. The study therefore supports further clinical investigation, not a safe and effective human regimen. It does not establish benefit across diabetes types or sexes, prevention of kidney failure, or longer life.
The paper reports research-related financial interests that readers should know about. Some authors disclosed advisory or consulting relationships, a financial interest related to the research, and patents on the senolytic drugs held by Mayo Clinic; other authors reported no conflicts. These disclosures do not determine whether the findings are correct, but they are part of the context for evaluating the work.
What this could mean for preserving kidney function
If the kidney-protective pattern seen in these mice can be reproduced in additional models and translated into a durable, acceptably safe regimen for people, treatment directed at senescent cells and their inflammatory effects could give people with diabetic kidney disease another way to limit persistent tissue injury and preserve kidney function. The short-course design makes that possibility worth investigating, but it does not yet promise a proven schedule or a lower treatment burden. The crucial future question is whether the combination can deliver lasting kidney benefit in people without relying on the glucose-lowering effect that this mouse experiment did not show.
Key Sources
- Primary source: Senolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease.
DOI or Journal Page · Peer-Reviewed Paper · 2026-01-20
Keep exploring